Which test are you looking for?

  • Alcat Test
  • CICA: Celiac, IBS, and Crohn’s Array
  • Adrenal Stress Profile
  • MethylDetox Profile
  • Telomere Test
  • Vitamin D

What are you looking to do?

Are you looking for a local doctor who provides testing?
Or would you prefer to speak to our laboratory specialists?

  • Local Doctor
  • Lab Specialist

Where should we send the list of local providers?

We look for providers in your area who are nearby and have great patient experience reviews.

You can expect to receive the list of providers within 24-48 hours

Sorry, something went wrong. Please try again.

Please complete all fields before submitting this form.

Thank you for your message! We'll reach out to you as soon as we can.

Great! Who should we contact?

Sorry, something went wrong. Please try again.

Please complete all fields before submitting this form.

Thank you for your message! We'll reach out to you as soon as we can.

GI issue prevalence in the United States

In the United States, an estimated 60-70 million people are affected by gastrointestinal disorders (GI). Celiac disease may be present despite the absence of GI symptoms, particularly, in relatives of individuals with celiac disease.1

  • In the U.S., 2 in 5 Americans are affected by GI disorders
  • Up to 20% of adults in North America suffer from irritable bowel syndrome (IBS)2
  • Approximately 0.44% of Americans experience Crohn’s disease and ulcerative colitis3
  • Up to 1% of the general population have symptoms of celiac disease4
  • 15% of the general population in western countries suffer from indigestion and constipation5, 6

Not surprisingly, there is overlap between these disorders.

Who may benefit

  • Those with gastrointestinal symptoms and autoimmune disorders that might suggest a problem with gluten
  • Those with increased intestinal permeability which has been linked to autoimmune disorders and other conditions
  • Those suspected to have Crohn’s or celiac disease
  • Those suffering from symptoms of IBS including diarrhea, bloating or cramping
  • Those with chronic fatigue
  • Those with malabsorption of nutrients and/or nutrient deficiency
  • Those with unexplained symptoms such as unintended weight loss or skin rash
  • Those seeking increased health efficiency or high performance lifestyle

Connecting the dots on celiac disease, non-celiac gluten sensitivity, and Crohn's disease

The CICA is a comprehensive test array that analyzes genetic predisposition, detects specific antibodies, and measures potentially inflammatory cellular reactions all through one simple blood draw.

Celiac disease risk analysis is determined based on the presence or absence of the HLA-DQ genotypes. Both the DQ8 and DQ2.5 genotypes are tested in this array, with the DQ2.5 genotypes representing a much greater risk of celiac disease.

Four specific serum antibodies (DGP IgG/IgA and tTG IgG/IgA) are tested due to their high sensitivity and specificity for active celiac disease. The higher the antibody levels, the more likely untreated celiac disease is present.

Genetic markers, mutations in the ATG16L1 and NOD2 genes, associated with the Crohn’s disease are tested along with serologic markers for complete assessment.

Anti-Saccharomyces Cerevisiae Antibody (ASCA; IgG/IgA) are immune proteins that are frequently present in people who have Crohn’s disease. The presence of ASCA may also reflect increased intestinal inflammation and permeability, including an association with active Crohn’s disease.

Testing Options & Test Results

Option 1: Celiac, IBS, and Crohn’s Array (CICA)
(Genetic + Serologic)

Option 2: CICA – Genetic Only

Option 3: CICA – Serologic/Antibody Only

CICA test results are color-coded and easy to read. Each result is thoroughly explained with expert commentary.

About Our lab

Cell Science Systems Corp. is a specialty clinical laboratory that develops and performs testing in immunology, serology, cell biology and molecular diagnostics supporting the personalized treatment and prevention of chronic disease.

Cell Science Systems Corp. operates a CLIA licensed laboratory and is an FDA inspected and registered, cGMP medical device manufacturer meeting ISO EN13485 2012 standards.

Committed to Quality

Cell Science Systems fulfills high quality state and federal standards.

  • CLIA-ID#10D0283906
  • State of Florida Lab ID: 800001500
  • State of California Lab ID: COS 00800633
  • EN13485
  • CE Marked. TUV Certified and safety monitored
  • Supported by the EU and the State of Brandenburg
  • ISO 13485:2012 + AC:2010 Certification as a Medical Device Manufacturer

Literature

1 Aggarwal S, Lebwohl B, Green PHR. Screening for celiac disease in average-risk and high-risk populations. Therap Adv Gastroenterol. 2012 Jan; 5(1): 37–47.

2 Hulisz D. The Burden of Illness of Irritable Bowel Syndrome: Current Challenges and Hope for the Future. J Manag Care Pharm. 2004;10(4):299-309

3 Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004 May;126(6):1504-17.

4 Gasbarrini GB, Mangiola F. Wheat-related disorders: A broad spectrum of ‘evolving’ diseases. United European Gastroenterol J. Aug 2014; 2(4): 254–262.

5 Saad RJ, Chey WD. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther. 2006; 24, 475–492

6 Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. Evidence-based position statement on the management of irritable bowel syndrome in North America. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Am J Gastroenterol. 2009;104(Suppl 1):S1-S35.